Announcements Trials
Browse Landscape

Status

Completed 3Active not recruiting 2Terminated 1Available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Conditions

Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Sarcoma 5Pancreatic Neoplasms 5Multiple Myeloma 5Melanoma 5Prostatic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myeloid, Acute 3Glioblastoma 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Recurrence 2Primary Myelofibrosis 2Non-Muscle Invasive Bladder Neoplasms 2Neuroblastoma 2Neoplasm Metastasis 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma 2Head and Neck Neoplasms 2Gastrointestinal Neoplasms 2Colorectal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Available × INDUSTRY × Lennox Gastaut Syndrome × Clear all
NCT06149663 2025-01-22

Intermediate-Size Expanded Access Protocol (EAP) for LP352

Longboard Pharmaceuticals

Available

CDKL5 deficiency disorder, Epilepsy, Epilepsies, Myoclonic, Tuberous Sclerosis, Lennox Gastaut Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡